Back to top
more

Haemonetics (HAE)

(Real Time Quote from BATS)

$57.44 USD

57.44
2,769,926

-18.33 (-24.19%)

Updated Aug 7, 2025 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on strong demand for NexSys PCS system and potential of Hemostasis Management franchise.

Zacks Equity Research

Haemonetics (HAE) Rides on Plasma Arm Recovery Amid COVID Woes

by Zacks Equity Research

Haemonetics' (HAE) hospital business is recovering primarily driven by continued improvement in hospital procedures.

Zacks Equity Research

Why Is Haemonetics (HAE) Up 4.9% Since Last Earnings Report?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

by Zacks Equity Research

Strong recovery across businesses and strength in plasma franchise benefited Haemonetics (HAE) during the first quarter of fiscal 2022.

Zacks Equity Research

Company News for Aug 12, 2021

by Zacks Equity Research

Companies In The News Are: WEN, HAE, RPRX, BLI

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings Top Estimates, Margins Improve

by Zacks Equity Research

Ongoing recovery in businesses, especially Hospital, and the initial Plasma Persona rollouts drove Haemonetics (HAE) fiscal first-quarter revenues.

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 6.38% and 1.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings Lag Estimates, Gross Margin Dips

by Zacks Equity Research

Haemonetics' (HAE) fourth-quarter fiscal 2021 revenues declined 5.6% year over year due to the pandemic.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of -31.34% and -0.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Haemonetics (HAE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Continued benefits from the NexSys device and NexLynk DMS along with robust TEG devices sales are expected to have contributed to Haemonetics (HAE) fourth-quarter top line.

Zacks Equity Research

Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays

by Zacks Equity Research

Omnicell (OMCL) expands its autonomous pharmacy portfolio with the acquisition of PSG's 340B Link business.

Zacks Equity Research

Reasons to Hold on to Syneos Health (SYNH) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.

Zacks Equity Research

Here's Why You Should Add Haemonetics (HAE) to Your Portfolio

by Zacks Equity Research

Investor are optimistic about Haemonetics (HAE) on its continued Plasma franchise growth and huge potential of Hemostasis Management franchise.

Zacks Equity Research

Haemonetics (HAE) Down 5.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts

by Zacks Equity Research

Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 19.12% and 6.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

MedTech Stock Earnings on Feb 2: IDXX, MCK & More

by Urmimala Biswas

In Q4, MedTech stocks are expected to have gained from month-wise sales rebound in many states and regions. However, international sales might have been dampened.

Zacks Equity Research

PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at Diagnostics segment.

Zacks Equity Research

McKesson (MCK) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

McKesson's (MCK) fiscal third-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

Zacks Equity Research

Haemonetics (HAE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ABIOMED (ABMD) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

The strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal third quarter as well.

Zacks Equity Research

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

by Zacks Equity Research

BD's (BDX) first-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.

Zacks Equity Research

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.